Skip to content
value.today

Senti Biosciences, Inc.

SNTI
$19 Mmarket cap on Oct 30, 2026-35.0% since Jan 2024
Compare
World rank
#24,528
Revenue
$0 M
For year ending December-2025
Net income
$-61 M
-307200.0% margin
SEC filing
Employees
39
As of March 19, 2026
SEC filing

Senti Biosciences, Inc. in brief

Senti Biosciences, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $19 M on 30 October 2026, which makes it the 24,528th largest listed company in the world and the 4,167th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $61 M. It employs about 39 people and Timothy K. Lu is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol SNTI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Senti Biosciences, Inc.

We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Using gene circuits, our product candidates are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration.

From the company's annual report filed with the US SEC: read the report

Senti Biosciences, Inc. timeline

5 events, 2021–2026
  1. 2021
  2. 🔔
    · approximate
    Initial public offering on Nasdaq
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2022
  5. 💰
    Record revenue of $4 million
    FY2022, the highest of the 4 years on record.
  6. ✎
    Renamed Senti Biosciences, Inc.\
    Formerly Dynamics Special Purpose Corp..
  7. 2026
  8. ✎
    Renamed Senti Biosciences Holdings, Inc.
    Formerly Senti Biosciences, Inc.\.

Events of Senti Biosciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$16 M$32 M$48 M$64 M2023202420252026

World rank over time

▼ down 128 places since 2022
2022-12-25: #24418#24,41820222023-07-30: #26409#26,40920232024-01-05: #27383#27,38320242026-03-08: #11843#11,84320262026-08-01: #22496#22,49620262026-10-14: #26219#26,21920262026-10-30: #24546#24,5462026

Rank in USA: #4,669 (Dec 2022) · #4,882 (Jul 2023) · #4,274 (Jan 2024) · #2,286 (Mar 2026) · #3,998 (Aug 2026) · #4,287 (Oct 2026) · #4,170 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
943.0×
Price / book
3.4×
Free cash flow yield
-231.4%
Net margin
-307200.0%
Operating margin
-343900.0%
Return on equity
-1099.1%
Liabilities / assets
89.1%
Revenue growth
-99.2%
R&D / revenue
187950.0%
Revenue per employee
$1 K
Profit per employee
$-1.6 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue $3M, net income $-55M$3MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-58M$4MFY22Fiscal year ending Dec 2023: revenue $3M, net income $-71M$3MFY23Fiscal year ending Dec 2024: revenue —, net income $-53M—FY24Fiscal year ending Dec 2025: revenue $0M, net income $-61M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M—$-69M$-61M-307200.0%
Dec 2024——$-61M$-53M—
Dec 2023$3M-40.3%$-93M$-71M-2775.8%
Dec 2022$4M+55.4%$-62M$-58M-1356.9%
Dec 2021$3M—$-40M$-55M-2004.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-43M$0M$-44M$-2.73—
Dec 2024$-41M$0M$-41M$-12.03—
Dec 2023$-52M$12M$-64M$-16.01—
Dec 2022$-35M$41M$-76M$-2.23—
Dec 2021$-35M$6M$-40M$-19.00—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-29M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-1M—Dec ’24Three months to Mar 2025: revenue —, net income $-14M—Mar ’25Three months to Jun 2025: revenue —, net income $-15M—Jun ’25Three months to Sep 2025: revenue —, net income $-18M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-14M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-4M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-13M$0MJun ’26

Latest quarter to Jun 2026: revenue $0M, net income $-13M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Senti Biosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-69 M
Net income
$-61 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$51 M
Total liabilities
$46 M
Total equity
$6 M

As of December-2025

Top 22 institutional investors in Senti Biosciences, Inc.#

As of Sep 30, 2026
22 institutions held 1.3 M shares (about 4.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.0%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 22 largest institutional investors in Senti Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC537,5040 (0.00%)1.73%$0 MNov 13, 2026
2Geode Capital Management, LLC176,602-10,463 (-5.59%)0.57%$0 MNov 6, 2026
3Two Sigma Securities, LLC153,480New0.49%$0 MNov 16, 2026
4GTS Securities LLC110,000New0.35%$0 MNov 16, 2026
5Vanguard Fiduciary Trust Co91,1930 (0.00%)0.29%$0 MNov 13, 2026
6HRT Financial LP53,827New0.17%$0 MNov 13, 2026
7Virtu Financial LLC47,271+24,476 (+107.37%)0.15%$0 MNov 17, 2026
8Menlo Ventures Management, L.P.35,7370 (0.00%)0.11%$0 MNov 6, 2026
9Northern Trust Corp32,1540 (0.00%)0.10%$0 MNov 16, 2026
10Susquehanna International Group, LLP23,147New0.07%$0 MNov 16, 2026
11UBS Group AG17,402+2,970 (+20.58%)0.06%$0 MNov 10, 2026
12Citadel Advisors LLC16,365-90,735 (-84.72%)0.05%$0 MNov 16, 2026
13XTX Topco Ltd14,885-8,725 (-36.95%)0.05%$0 MNov 16, 2026
14State Street Corp10,0100 (0.00%)0.03%$0 MNov 12, 2026
15Nuveen, LLC9,819New0.03%$0 MNov 10, 2026
16Tower Research Capital LLC (TRC)8,959+1,615 (+21.99%)0.03%$0 MNov 16, 2026
17Royal Bank Of Canada4,0150 (0.00%)0.01%$0 MNov 16, 2026
18SBI Securities Co., Ltd.523+189 (+56.59%)0.00%$0 MOct 22, 2026
19BlackRock, Inc.262-3,742 (-93.46%)0.00%$0 MNov 13, 2026
20Morgan Stanley160-9 (-5.33%)0.00%$0 MNov 13, 2026
21Barclays PLC10-758 (-98.70%)0.00%$0 MNov 6, 2026
22Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding Senti Biosciences, Inc.#

6 funds hold shares worth $1 M (about 2.2% of the company). Since their previous reports 6 added shares and 0 sold, buying $1 M net.
Mutual funds holding Senti Biosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.368,878$0 M1.2%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.168,626$0 M0.54%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC95,866$0 M0.31%<0.01%newMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC24,798$0 M0.08%<0.01%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC19,991$0 M0.06%<0.01%newMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC18,801$0 M0.06%<0.01%newMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Senti Biosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
9
since
Senti Biosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kanya RajangamPres. & Chief Med. & Dev. Off.Shares withheld for tax-19,953——54,890Form 4
filed Timothy K. LuCEO, DirectorShares withheld for tax-157,312——482,271Form 4
filed Timothy K. LuCEO, DirectorShares withheld for tax-80,666——639,583Form 4
filed Kanya RajangamPres. & Chief Med. & Dev. Off.Shares withheld for tax-10,757——74,843Form 4
filed Timothy K. LuCEO, DirectorShares withheld for tax-4,191——720,249Form 4
filed Kanya RajangamPres. & Chief Med. & Dev. Off.Shares withheld for tax-1,384——85,600Form 4
filed Celadon Partners SPV 2410% ownerConversion+9.78 M——9.78 MForm 4
filed Anthony A. Florence Jr.10% ownerConversion+3.33 M——3.78 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Senti Biosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.1 M
3.6% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split

Trading halts

  • 2026-11-19 00:50 UTC, code T3, resumed 14:00 UTC
  • 2026-07-15 11:25 UTC, code T3, resumed 12:00 UTC
  • 2025-02-28 15:01 UTC, code LUDP, resumed 15:06 UTC
  • 2025-02-28 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2025-02-28 14:41 UTC, code LUDP, resumed 14:46 UTC

Fails to deliver

  • : 802,064 shares at $0.22
  • : 792,173 shares at $0.22
  • : 1.7 M shares at $0.19
  • : 2.2 M shares at $0.18
  • : 13,225 shares at $0.19

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Senti Biosciences, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.4×Price to book 3.4× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median943.0×Price to sales 943.0× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.73 vs -12.03Diluted EPS -2.73 in fiscal 2025 against -12.03 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$61 MNet income -$61 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-393.3%-393.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.67 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-13.77Z-score -13.77 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year389.2%Diluted shares up 389.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Senti Biosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Senti Biosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue0.002.64.32.8
Research and development38343228r22
General and administrative26263738r21
Operating expenses69619566r43
Operating income−69−61−93−62r−40
Other non-operating income (expense)7.38.29.312−15
Income tax00———
Income from continuing operations−61−53−83−50—
Income from discontinued operations—012−8.5—
Net income attributable to shareholders−61−53−71−58−55
Earnings per share, basic-2.73-12.03-16.01r-2.23-19.00
Earnings per share, diluted-2.73-12.03-16.01r-2.23-19.00
Shares, weighted average (basic)224.64.4r262.9
Shares, weighted average (diluted)224.64.4r262.9
Balance sheet
Cash and cash equivalents1648365856r
Short-term investments——0410
Receivables———0.60.5
Other current assets00.60.20.10.3
Current assets23597110360r
Property, plant and equipment13212551r12
Right-of-use (leased) assets1214161821
Total assets519811918197r
Accounts payable2.91.51.31.4r5.2
Current liabilities1413131815r
Lease liabilities (non-current)2429343521
Total liabilities4647535436r
Retained earnings−359−297−244−173−115r
Shareholders' equity5.62667127−111r
Total liabilities and equity519811918197r
Shares outstanding314.84.6r443.0
Cash-flow statement
Share-based compensation5.71.89.7162.3
Cash from operating activities−43−41−52−35−35
Capital expenditure−0.2−0.0−12−41−5.5
Cash from investing activities−0.20.030−82−5.5
Shares issued—1.80.50.70
Cash from financing activities12540.811968
Change in cash−3212−221.728
Report10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Senti Biosciences, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$0 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Senti Biosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 10 · Agreement ended 1 · New debt 4 · Unregistered share sale 3 · Shareholder vote 3 · Results announced 8

Senti Biosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share sale8-K
Directors and officers8-K
Acquisition or sale completedMaterial agreementAgreement endedUnregistered share sale8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementNew debt8-K
Delisting noticeMaterial agreement8-K
Material agreementNew debt8-K
Change in controlMaterial agreementResults announced8-K
Material agreementNew debt8-K
Results announced8-K
Change in controlMaterial agreementNew debtUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Senti Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$38 MPrivate placement after listing$10 to $50 million15equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Senti Biosciences, Inc.#

6 labor condition applications certified in fiscal 2024 for 6 positions, at a median wage of $120 K a year.

Certified, FY2024
6
#1,085 among companies on value.today
Worker positions
6
Median wage offered
$120 K
a year, full-time
Applications filed
6
Senti Biosciences, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Scientist IIBiochemists and Biophysicists1—
Senior Research Associate I, PreClinical ResearchMolecular and Cellular Biologists1$102 K
Senior Research Associate I, Process ScienceMolecular and Cellular Biologists1$102 K
Senior ScientistBioinformatics Scientists1$120 K
Senior Scientist I, Gene Circuit Discovery (HTS)Biochemists and Biophysicists1$145 K
Senior Scientist II, Process DevelopmentBiochemists and Biophysicists1$175 K

Where: South San Francisco, CA 6

Senti Biosciences, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202466$120 K6
FY202377$129 K7
FY202222$128 K2
FY202111$129 K1
FY202033$83 K3

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Senti Biosciences, Inc.

Layoffs at Senti Biosciences, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-01-03
Senti Biosciences, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
Senti Biosciences, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
37% of workforceRestructuring planSEC 8-K“Pursuant to these plans, the Company is reducing its workforce by approximately 37%.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Senti Biosciences, Inc. compares in Biotechnology

  • Market cap$19 M · higher than 17% of 726
  • Revenue$0 M · higher than 13% of 647
  • Price / sales943.0× · lower than 0% of 339
  • Price / book3.4× · lower than 44% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Senti Biosciences, Inc.🇺🇸$19 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 19, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Senti Biosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Senti Biosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Senti Biosciences, Inc.? Suggest a correction